<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The pathogenesis of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> is closely associated with <z:mp ids='MP_0001845'>inflammation</z:mp> and immune response in arterial walls </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, the authors proved the key role of Toll-like receptor (TLR)4 in the development of vasospasm in experimental <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) model </plain></SENT>
<SENT sid="2" pm="."><plain>Because peroxisome proliferator-activated receptor (PPAR) gamma <z:chebi fb="4" ids="48705">agonists</z:chebi> are identified as effective inhibitors of TLR4 activation, we investigated the anti-<z:mp ids='MP_0001845'>inflammation</z:mp> properties of PPAR-gamma <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> in basilar arteries in a rat experimental SAH model and evaluated the effects of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> on vasospasm </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0001845'>Inflammatory responses</z:mp> in basilar arteries were assessed by immunohistochemical staining for intercellular molecule (ICAM)-1 and myeloperoxidase (MPO) </plain></SENT>
<SENT sid="4" pm="."><plain>Expression of TLR4 was determined by western blot analysis </plain></SENT>
<SENT sid="5" pm="."><plain>The degree of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> was evaluated by measuring the mean diameter and cross-sectional area of basilar arteries </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> suppressed the SAH-induced <z:mp ids='MP_0001845'>inflammatory responses</z:mp> in basilar arteries by inhibiting the TLR4 signalling </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> could attenuate <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following SAH </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, we suggested that PPAR-gamma <z:chebi fb="4" ids="48705">agonists</z:chebi> may be potential therapeutic agents for <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
</text></document>